Form 4: Rhythm Pharma CHRO Sells Shares After Option Exercise

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, executed pre-planned sales of common stock following the exercise of stock options.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions involving the company's common stock and stock options.
• On November 7, 2025, Cramer acquired 8,805 shares of common stock by exercising stock options at a price of $19.02 per share.
• Also on November 7, 2025, Cramer acquired an additional 10,546 shares of common stock by exercising stock options at a price of $6.8 per share.
• On the same day, November 7, 2025, Cramer disposed of 19,351 shares of common stock at a price of $98.8231 per share.
• On November 10, 2025, Cramer acquired 3,515 shares of common stock by exercising stock options at a price of $6.8 per share.
• Also on November 10, 2025, Cramer disposed of 3,515 shares of common stock at a price of $100 per share.
• All sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Cramer on August 7, 2025.
• Following these transactions, Cramer beneficially owns 20,814 shares of common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as an officer is realizing gains from vested options, which is a normal part of executive compensation. The pre-planned nature of the sales under a 10b5-1 plan reduces any negative implications of insider selling.

Positives

• The Chief Human Resources Officer realized significant gains by selling shares at prices substantially higher than her option exercise prices (e.g., selling at $98.8231 and $100 after exercising at $19.02 and $6.8).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, non-opportunistic sale rather than a reaction to recent events.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, although the context of option exercise often mitigates this concern.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the officer's profitable exercise and sale of options as a positive sign of the company's stock performance, though the reduction in insider holdings could be a minor concern for some.

Key Dates

Recommendation

This filing details a routine, pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares by a Chief Human Resources Officer. Such transactions, executed under a Rule 10b5-1 plan, are generally not indicative of a change in company fundamentals or management's long-term outlook. Therefore, this specific filing does not provide new information that would warrant a change from a 'hold' recommendation.

Keywords

Rhythm Pharmaceuticals, RYTM, Insider Trading, Form 4, Stock Options, Equity Sales, Pamela J. Cramer, 10b5-1 Plan